188 related articles for article (PubMed ID: 33607457)
21. Synthesis and biological evaluation of a MraY selective analogue of tunicamycins.
Yamamoto K; Sato T; Hikiji Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):349-364. PubMed ID: 31566068
[TBL] [Abstract][Full Text] [Related]
22. Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.
Kimura KI
J Antibiot (Tokyo); 2019 Dec; 72(12):877-889. PubMed ID: 31582803
[TBL] [Abstract][Full Text] [Related]
23. Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of their derivatives.
Lin YI; Li Z; Francisco GD; McDonald LA; Davis RA; Singh G; Yang Y; Mansour TS
Bioorg Med Chem Lett; 2002 Sep; 12(17):2341-4. PubMed ID: 12161129
[TBL] [Abstract][Full Text] [Related]
24. Natural Products at Work: Structural Insights into Inhibition of the Bacterial Membrane Protein MraY.
Koppermann S; Ducho C
Angew Chem Int Ed Engl; 2016 Sep; 55(39):11722-4. PubMed ID: 27511599
[TBL] [Abstract][Full Text] [Related]
25. Lead structures for new antibacterials: stereocontrolled synthesis of a bioactive muraymycin analogue.
Spork AP; Büschleb M; Ries O; Wiegmann D; Boettcher S; Mihalyi A; Bugg TD; Ducho C
Chemistry; 2014 Nov; 20(47):15292-7. PubMed ID: 25318977
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors.
Dini C; Collette P; Drochon N; Guillot JC; Lemoine G; Mauvais P; Aszodi J
Bioorg Med Chem Lett; 2000 Aug; 10(16):1839-43. PubMed ID: 10969981
[TBL] [Abstract][Full Text] [Related]
27. A Sub-Micromolar MraY
Oliver M; Le Corre L; Poinsot M; Bosco M; Wan H; Amoroso A; Joris B; Bouhss A; Calvet-Vitale S; Gravier-Pelletier C
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335131
[TBL] [Abstract][Full Text] [Related]
28. Self-Resistance during Muraymycin Biosynthesis: a Complementary Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct Temporal Order.
Cui Z; Wang XC; Liu X; Lemke A; Koppermann S; Ducho C; Rohr J; Thorson JS; Van Lanen SG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735559
[TBL] [Abstract][Full Text] [Related]
29. 5'-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling.
Fer MJ; Bouhss A; Patrão M; Le Corre L; Pietrancosta N; Amoroso A; Joris B; Mengin-Lecreulx D; Calvet-Vitale S; Gravier-Pelletier C
Org Biomol Chem; 2015 Jul; 13(26):7193-222. PubMed ID: 26008868
[TBL] [Abstract][Full Text] [Related]
30. MraY-antibiotic complex reveals details of tunicamycin mode of action.
Hakulinen JK; Hering J; Brändén G; Chen H; Snijder A; Ek M; Johansson P
Nat Chem Biol; 2017 Mar; 13(3):265-267. PubMed ID: 28068312
[TBL] [Abstract][Full Text] [Related]
31. Scintillation proximity assay for inhibitors of Escherichia coli MurG and, optionally, MraY.
Ravishankar S; Kumar VP; Chandrakala B; Jha RK; Solapure SM; de Sousa SM
Antimicrob Agents Chemother; 2005 Apr; 49(4):1410-8. PubMed ID: 15793120
[TBL] [Abstract][Full Text] [Related]
32. Analogues of Muraymycin Nucleoside Antibiotics with Epimeric Uridine-Derived Core Structures.
Spork AP; Koppermann S; Schier Née Wohnig S; Linder R; Ducho C
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400295
[TBL] [Abstract][Full Text] [Related]
33. Bacterial Transferase MraY, a Source of Inspiration towards New Antibiotics.
Fer MJ; Corre LL; Pietrancosta N; Evrard-Todeschi N; Olatunji S; Bouhss A; Calvet-Vitale S; Gravier-Pelletier C
Curr Med Chem; 2018; 25(42):6013-6029. PubMed ID: 29600753
[TBL] [Abstract][Full Text] [Related]
34. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.
Siricilla S; Mitachi K; Skorupinska-Tudek K; Swiezewska E; Kurosu M
Anal Biochem; 2014 Sep; 461():36-45. PubMed ID: 24939461
[TBL] [Abstract][Full Text] [Related]
35. Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins.
Hering J; Dunevall E; Snijder A; Eriksson PO; Jackson MA; Hartman TM; Ting R; Chen H; Price NPJ; Brändén G; Ek M
ACS Chem Biol; 2020 Nov; 15(11):2885-2895. PubMed ID: 33164499
[TBL] [Abstract][Full Text] [Related]
36. Structural requirement of tunicamycin V for MraY inhibition.
Yamamoto K; Katsuyama A; Ichikawa S
Bioorg Med Chem; 2019 Apr; 27(8):1714-1719. PubMed ID: 30850266
[TBL] [Abstract][Full Text] [Related]
37. Muraymycin nucleoside-peptide antibiotics: uridine-derived natural products as lead structures for the development of novel antibacterial agents.
Wiegmann D; Koppermann S; Wirth M; Niro G; Leyerer K; Ducho C
Beilstein J Org Chem; 2016; 12():769-795. PubMed ID: 27340469
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of an Antimicrobial Enterobactin-Muraymycin Conjugate for Improved Activity Against Gram-Negative Bacteria.
Rohrbacher C; Zscherp R; Weck SC; Klahn P; Ducho C
Chemistry; 2023 Jan; 29(5):e202202408. PubMed ID: 36222466
[TBL] [Abstract][Full Text] [Related]
39. Ligand Shaping in Induced Fit Docking of MraY Inhibitors. Polynomial Discriminant and Laplacian Operator as Biological Activity Descriptors.
Lungu CN; Diudea MV; Putz MV
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653980
[TBL] [Abstract][Full Text] [Related]
40. New Insight into the Catalytic Mechanism of Bacterial MraY from Enzyme Kinetics and Docking Studies.
Liu Y; Rodrigues JP; Bonvin AM; Zaal EA; Berkers CR; Heger M; Gawarecka K; Swiezewska E; Breukink E; Egmond MR
J Biol Chem; 2016 Jul; 291(29):15057-68. PubMed ID: 27226570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
